27485101|t|MicroRNA-26a protects against cardiac hypertrophy via inhibiting GATA4 in rat model and cultured cardiomyocytes.
27485101|a|Pathological cardiac hypertrophy is characterized by deleterious changes developed in cardiovascular diseases, whereas microRNAs (miRNAs) are involved in the mediation of cardiac hypertrophy. To investigate the role of microRNA-26a (miR-26a) in regulating cardiac hypertrophy and its functioning mechanisms, overexpression and suppression of miR-26a via its mimic and inhibitor in a transverse abdominal aortic constriction (TAAC)- induced rat model and in angiotensin II (Ang II)- induced cardiomyocytes (CMs) was performed. In the rat model, the heart weight (HW) compared with the body weight (BW), the CM area, and expression of the hypertrophy - associated factors, atrial natriuretic factor (ANF) and ß-myosin heavy chain (ß-MHC), were assessed. In CMs, the protein synthesis rate was determined using a leucine incorporation assay. Mutation of the GATA-binding protein 4 (GATA4) 3'-untranslated region (UTR) and overexpression of GATA4 were performed to confirm whether GATA4 is the target of miR-26a. The results indicated that miR-26a was significantly downregulated in the heart tissue of the rat model, as well as in Ang II - induced CMs (P<0.05). The TAAC - induced rat model exhibited a higher HW / BW ratio, a larger CM area, and higher expression levels of ANF and ß-MHC. CMs, upon Ang II treatment, also demonstrated a larger CM area, higher levels of ANF and ß-MHC, as well as accelerated protein synthesis. miR-26a was not able to regulate GATA4 with mutations in the 3'-UTR, indicating that GATA4 was the direct target of miR-26a. Overexpression of GATA4 abrogated the inhibitory functions of miR-26a in cardiac hypertrophy. Taken together, the present study suggested an anti-hypertrophic role of miR-26a in cardiac hypertrophy, possibly via inhibition of GATA4. These findings may be useful in terms of facilitating cardiac treatment, with potential therapeutic targets and strategies.
27485101	0	12	MicroRNA-26a	T114	C3179934
27485101	13	21	protects	T033	C1545588
27485101	22	29	against	T080	C0521124
27485101	30	49	cardiac hypertrophy	T046	C1383860
27485101	54	64	inhibiting	T052	C3463820
27485101	65	70	GATA4	T028	C1414995
27485101	74	77	rat	T015	C0034721
27485101	78	83	model	T008	C0599779
27485101	88	111	cultured cardiomyocytes	T025	C0007635
27485101	97	111	cardiomyocytes	T025	C0225828
27485101	113	125	Pathological	T169	C1521733
27485101	126	145	cardiac hypertrophy	T046	C1383860
27485101	166	177	deleterious	T052	C1880274
27485101	178	185	changes	T169	C0392747
27485101	199	222	cardiovascular diseases	T047	C0007222
27485101	232	241	microRNAs	T114,T123	C1101610
27485101	243	249	miRNAs	T114,T123	C1101610
27485101	284	303	cardiac hypertrophy	T046	C1383860
27485101	308	319	investigate	T169	C1292732
27485101	332	344	microRNA-26a	T114	C3179934
27485101	346	353	miR-26a	T114	C3179934
27485101	358	388	regulating cardiac hypertrophy	T046	C2611906
27485101	397	408	functioning	T042	C0232164
27485101	409	419	mechanisms	T169	C0441712
27485101	421	435	overexpression	T045	C0017262
27485101	440	451	suppression	T045	C0038855
27485101	455	462	miR-26a	T028	C2825314
27485101	471	476	mimic	T044	C0242943
27485101	481	490	inhibitor	T120	C0243077
27485101	496	506	transverse	T082	C0205106
27485101	507	516	abdominal	T029	C0000726
27485101	517	536	aortic constriction	T046	C0597891
27485101	538	542	TAAC	T046	C0597891
27485101	545	552	induced	T169	C0205263
27485101	553	556	rat	T015	C0034721
27485101	557	562	model	T008	C0599779
27485101	570	584	angiotensin II	T116,T121,T123	C0003009
27485101	586	592	Ang II	T116,T121,T123	C0003009
27485101	595	602	induced	T169	C0205263
27485101	603	617	cardiomyocytes	T025	C0225828
27485101	619	622	CMs	T025	C0225828
27485101	646	649	rat	T015	C0034721
27485101	650	655	model	T008	C0599779
27485101	661	673	heart weight	T081	C0043100
27485101	675	677	HW	T081	C0043100
27485101	697	708	body weight	T032	C0005910
27485101	710	712	BW	T032	C0005910
27485101	719	721	CM	T025	C0225828
27485101	722	726	area	T082	C0205146
27485101	732	742	expression	T078	C3854321
27485101	750	761	hypertrophy	T046	C0020564
27485101	764	774	associated	T080	C0439849
27485101	775	782	factors	T169	C1521761
27485101	784	809	atrial natriuretic factor	T116,T123	C0027481
27485101	811	814	ANF	T116,T123	C0027481
27485101	820	840	ß-myosin heavy chain	T116,T123	C1451796
27485101	842	847	ß-MHC	T116,T123	C1451796
27485101	855	863	assessed	T052	C1516048
27485101	868	871	CMs	T025	C0225828
27485101	877	894	protein synthesis	T044	C0597295
27485101	895	899	rate	T081	C1521828
27485101	923	950	leucine incorporation assay	T059	C0005507
27485101	952	960	Mutation	T045	C0026882
27485101	968	990	GATA-binding protein 4	T028	C1414995
27485101	992	997	GATA4	T028	C1414995
27485101	999	1021	3'-untranslated region	T086,T123	C0600600
27485101	1023	1026	UTR	T086,T123	C0600600
27485101	1032	1046	overexpression	T045	C1514559
27485101	1050	1055	GATA4	T028	C1414995
27485101	1090	1095	GATA4	T028	C1414995
27485101	1103	1109	target	T169	C1521840
27485101	1113	1120	miR-26a	T114	C3179934
27485101	1149	1156	miR-26a	T114	C3179934
27485101	1175	1188	downregulated	T044	C0013081
27485101	1196	1208	heart tissue	T024	C1272575
27485101	1216	1219	rat	T015	C0034721
27485101	1220	1225	model	T008	C0599779
27485101	1241	1247	Ang II	T116,T121,T123	C0003009
27485101	1250	1257	induced	T169	C0205263
27485101	1258	1261	CMs	T025	C0225828
27485101	1276	1280	TAAC	T046	C0597891
27485101	1283	1290	induced	T169	C0205263
27485101	1291	1294	rat	T015	C0034721
27485101	1295	1300	model	T008	C0599779
27485101	1313	1319	higher	T080	C0205250
27485101	1320	1322	HW	T081	C0043100
27485101	1325	1327	BW	T032	C0005910
27485101	1328	1333	ratio	T081	C0456603
27485101	1337	1343	larger	T081	C0549177
27485101	1344	1346	CM	T025	C0225828
27485101	1347	1351	area	T082	C0205146
27485101	1357	1363	higher	T080	C0205250
27485101	1364	1374	expression	T045	C1171362
27485101	1375	1381	levels	T080	C0441889
27485101	1385	1388	ANF	T116,T123	C0027481
27485101	1393	1398	ß-MHC	T116,T123	C1451796
27485101	1400	1403	CMs	T025	C0225828
27485101	1410	1416	Ang II	T116,T121,T123	C0003009
27485101	1417	1426	treatment	T061	C0087111
27485101	1455	1457	CM	T025	C0225828
27485101	1458	1462	area	T082	C0205146
27485101	1464	1470	higher	T080	C0205250
27485101	1471	1477	levels	T080	C0441889
27485101	1481	1484	ANF	T116,T123	C0027481
27485101	1489	1494	ß-MHC	T116,T123	C1451796
27485101	1507	1518	accelerated	T169	C0521110
27485101	1519	1536	protein synthesis	T044	C0597295
27485101	1538	1545	miR-26a	T114	C3179934
27485101	1562	1570	regulate	T038	C1327622
27485101	1571	1576	GATA4	T028	C1414995
27485101	1582	1591	mutations	T045	C0026882
27485101	1599	1605	3'-UTR	T086,T123	C0600600
27485101	1623	1628	GATA4	T028	C1414995
27485101	1644	1650	target	T169	C1521840
27485101	1654	1661	miR-26a	T114	C3179934
27485101	1663	1677	Overexpression	T045	C1514559
27485101	1681	1686	GATA4	T028	C1414995
27485101	1701	1721	inhibitory functions	T042	C0234122
27485101	1725	1732	miR-26a	T114	C3179934
27485101	1736	1755	cardiac hypertrophy	T046	C1383860
27485101	1804	1821	anti-hypertrophic	T033	C0243095
27485101	1822	1826	role	T077	C1705810
27485101	1830	1837	miR-26a	T114	C3179934
27485101	1841	1860	cardiac hypertrophy	T046	C1383860
27485101	1875	1885	inhibition	T052	C3463820
27485101	1889	1894	GATA4	T028	C1414995
27485101	1902	1910	findings	T033	C0243095
27485101	1950	1957	cardiac	T023	C0018787
27485101	1958	1967	treatment	T061	C0087111
27485101	1974	1983	potential	T080	C3245505
27485101	1984	1995	therapeutic	T169	C0302350
27485101	1996	2003	targets	T169	C1521840